Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News CRT 2021

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

Michael O'Riordan

March 17, 2021

News Industry News

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

July 23, 2019

News Daily News

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Michael O'Riordan

April 30, 2019

News Opinion Off Script TCT 2018

Off Script: Phantom Hearts and the Elusive Nature of Angina

Kwan S. Lee

October 11, 2018

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

News Daily News

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Michael O'Riordan

October 17, 2017

News Features

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Michael O'Riordan

September 13, 2017

News Daily News

Boston Scientific Scraps Biodegradable Scaffold Program

Michael O'Riordan

August 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Features

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Michael O'Riordan

May 08, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Advertisement

Good Long-term Results With FANTOM BVS, but More Data Needed

COMPARE-ABSORB: 3-Year Results Hint at Stabilization With Bioresorbable Scaffold

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

Three Years On, Absorb BVS Still Doesn’t Improve Myocardial Blood Flow

Off Script: Phantom Hearts and the Elusive Nature of Angina

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

The Biggest News of 2017: TCTMD’s Top 10

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Long-term Absorb BVS Data Continue to Disappoint

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Absorb BVS Again Linked to Scaffold Thrombosis at 1 Year and Beyond

Absorb Vanishes, but Can Other Bioresorbable Scaffolds Make Magic Happen?

Boston Scientific Scraps Biodegradable Scaffold Program

TCTMD’s Top 10 Most Popular Stories for May 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Absorb in Europe: When, How, and by Whom the Beleaguered BVS Is Being Used After Restrictions

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content